GLP-1 side effects and real talk: what TikTok gets wrong

What's this video probably claiming?

Without a transcript, we're working from context clues: @carinaeberle posts in the GLP-1 space and has built a significant audience, likely through personal experience content around semaglutide or tirzepatide use. Videos in this category with high view counts (357K is not trivial) typically fall into a few predictable buckets: before-and-after framing, side effect confessionals, dosing journey updates, or pushback against GLP-1 skeptics. Given the category tag and the creator's profile, this is most likely a personal experience video discussing weight loss progress, nausea management, appetite suppression, or the emotional experience of being on a GLP-1 medication. That content is not inherently wrong, but personal anecdote and clinical evidence are two different things, and TikTok has a consistent problem conflating them at scale.

What does the science actually show?

GLP-1 receptor agonists are among the most rigorously studied weight loss interventions in modern medicine. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15mg produced mean body weight reduction of 20.9% over 72 weeks in adults with obesity. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg weekly produced 14.9% mean weight loss over 68 weeks. These are not small numbers. Gastrointestinal side effects, primarily nausea, vomiting, and constipation, affected 40 to 50% of participants in both trials but were mostly transient and tied to dose escalation periods. Serious adverse events were low. Importantly, weight regain after stopping the medication is well-documented. The STEP 4 withdrawal trial (Rubino et al., 2021, JAMA) showed participants regained two-thirds of lost weight within one year of discontinuation. That context almost never makes it into TikTok content.

Where does the social media noise diverge from clinical reality?

The gap between TikTok GLP-1 content and clinical reality is wide, and it runs in both directions. Some creators overstate benefits, presenting dramatic weight loss as typical without acknowledging the 20 to 30% of trial participants who are poor responders. Others lean into fear-based content, treating manageable side effects like nausea as universally severe. A particularly common distortion is the framing of GLP-1 medications as passive solutions, where the drug does the work and lifestyle changes are optional. The SCALE trial data for liraglutide (Pi-Sunyer et al., 2015, NEJM) and subsequent semaglutide research consistently show that behavioral intervention alongside medication produces meaningfully better outcomes than medication alone. There is also near-total silence on TikTok about the current compounded semaglutide situation, the FDA's shortage designations, and why compounded versions are not equivalent to FDA-approved branded products. That omission matters for anyone making treatment decisions based on social content.

What should you actually know?

GLP-1 medications are legitimate, well-studied tools. The clinical evidence is real and the effect sizes are meaningful by any standard. But personal experience videos, however authentic, are not a substitute for individualized medical evaluation. A few things worth knowing before forming opinions based on creator content: response varies significantly between individuals, and the people posting dramatic results are not a representative sample. Side effect severity correlates with how quickly doses are escalated, something a prescribing clinician should manage. Long-term data beyond three to five years is still limited for most of these agents. And perhaps most importantly, the chronic disease model framing of obesity, which the clinical literature increasingly supports, means these medications are not short-term fixes. Anyone considering a GLP-1 medication should be having that conversation with a licensed provider, not calibrating expectations against a 60-second video.